BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Charuel E, Menini T, Bedhomme S, Pereira B, Piñol-Domenech N, Bouchant S, Boussageon R, Bœuf-Gibot S, Vaillant-Roussel H. Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis. Pharmacol Res Perspect 2021;9:e00844. [PMID: 34617669 DOI: 10.1002/prp2.844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Gao J, Zhao C, Zhang WZ, Liu S, Xin H, Lian ZX. Efficacy and safety profile of angiotensin receptor neprilysin inhibitors in the management of heart failure: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev 2022. [PMID: 36184714 DOI: 10.1007/s10741-022-10273-3] [Reference Citation Analysis]
2 Song Y, Zhao Z, Zhang J, Zhao F, Jin P. Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.922721] [Reference Citation Analysis]
3 Tian Q, Xiong Z, Fan H, Ning T, Zheng Z. The Efficacy and Safety of Sacubitril-Valsartan for the Treatment of Heart Failure in Adults: A Meta-Analysis. Ann Pharmacother 2022;:10600280221112158. [PMID: 35915995 DOI: 10.1177/10600280221112158] [Reference Citation Analysis]